The Ontario startup combines AI with trained human professionals to help patients navigate PCOS, endometriosis, fertility, and perimenopause, the conditions with the longest diagnostic delays and most fragmented care in the system. Graphite Ventures led the round.
When a patient receives a specialist referral, a confusing test result, or a diagnosis that landed in their portal before their doctor called, the healthcare system quietly hands them a second job.
They become their own project manager, medical historian, insurance coordinator, and advocate, with no training, no tools, and no support. myStoria is building the infrastructure for that person.
The startup has raised $1.625 million in a seed round led by Graphite Ventures, with participation from Conexus Venture Capital, Adrenaline Fund, Phoenix Fire Fund, and a group of strategic angel investors.
The 💜 of EU tech
The latest rumblings from the EU tech scene, a story from our wise ol’ founder Boris, and some questionable AI art. It’s free, every week, in your inbox. Sign up now!
The company started in reproductive health, specifically fertility and IVF, conditions with notoriously high dismissal rates, the longest diagnostic delays, and the most fragmented care pathways of any area of medicine.
Founder and CEO Jessica Chalk spent six years navigating infertility personally, going through multiple treatments at a personal cost exceeding $100,000, before building the platform she needed and could not find.
The seed round expands myStoria’s scope across the full reproductive health lifecycle: PCOS, endometriosis, perimenopause, and hormonal health will all be covered, each with condition-specific pathways.
The platform combines AI with trained human professionals in a human-in-the-loop model. At its core is a “Context Engine”, a proprietary layer that organises a user’s complete health picture, including documents, audio, photos, symptoms, and appointment history, into a structured format optimised for AI comprehension.
Every interaction builds on that retained history. Trained professionals review AI-generated guidance and add clinical context. The aim is responses that are personal, accurate, and grounded in the full picture rather than generic information returns.
The platform launches on iOS and Android with a freemium model.
Aaron Bast, GP at Graphite Ventures, framed the investment in infrastructure terms: myStoria is “not just another consumer app,” but a “defensible infrastructure play” that owns the patient’s longitudinal health data.
Graphite, which focuses on seed-stage B2B and digital health companies across Canada, typically writes cheques in the $500K to $1.5M range.
The myStoria round is at the top of that band with the broader syndicate included. Alex Shimla, Principal at Conexus Venture Capital, described the company as “creating the patient-owned infrastructure the system has been missing.”
The longer-term vision is explicitly not condition-specific: reproductive health is the wedge into a model that could eventually serve patients navigating cancer, heart disease, autoimmune conditions, any complex care situation where the patient has become their own care coordinator.
